hrcak mascot   Srce   HID

Sažetak sa skupa

Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats

Slaven Gojković ; Department of Pharmacology Univeristy of Zagreb School of Medicine
Hrvoje Vraneš ; Department of Pharmacology Univeristy of Zagreb School of Medicine
Zoya Jelovečki – Dokić ; Department of Pharmacology Univeristy of Zagreb School of Medicine
Oliver Marcel Koltay ; Department of Pharmacology Univeristy of Zagreb School of Medicine
Will Migo
Dominik Malekinušić ; Department of Pharmacology Univeristy of Zagreb School of Medicine

Puni tekst: engleski, pdf (67 KB) str. 0-0 preuzimanja: 13* citiraj
APA 6th Edition
Gojković, S., Vraneš, H., Jelovečki – Dokić, Z., Marcel Koltay, O., Migo, W. i Malekinušić, D. (2019). Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats. Liječnički vjesnik, 141 (suppl.1), 0-0. Preuzeto s https://hrcak.srce.hr/224625
MLA 8th Edition
Gojković, Slaven, et al. "Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats." Liječnički vjesnik, vol. 141, br. suppl.1, 2019, str. 0-0. https://hrcak.srce.hr/224625. Citirano 26.01.2020.
Chicago 17th Edition
Gojković, Slaven, Hrvoje Vraneš, Zoya Jelovečki – Dokić, Oliver Marcel Koltay, Will Migo i Dominik Malekinušić. "Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats." Liječnički vjesnik 141, br. suppl.1 (2019): 0-0. https://hrcak.srce.hr/224625
Harvard
Gojković, S., et al. (2019). 'Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats', Liječnički vjesnik, 141(suppl.1), str. 0-0. Preuzeto s: https://hrcak.srce.hr/224625 (Datum pristupa: 26.01.2020.)
Vancouver
Gojković S, Vraneš H, Jelovečki – Dokić Z, Marcel Koltay O, Migo W, Malekinušić D. Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats. Liječnički vjesnik [Internet]. 2019 [pristupljeno 26.01.2020.];141(suppl.1):0-0. Dostupno na: https://hrcak.srce.hr/224625
IEEE
S. Gojković, H. Vraneš, Z. Jelovečki – Dokić, O. Marcel Koltay, W. Migo i D. Malekinušić, "Pentadecapeptide BPC 157 counteracts portal hypertension, caval hypertension and aortal hypotension with suprahepatic occlusion of inferior caval vein in rats", Liječnički vjesnik, vol.141, br. suppl.1, str. 0-0, 2019. [Online]. Dostupno na: https://hrcak.srce.hr/224625. [Citirano: 26.01.2020.]

Sažetak
Portal hypertension, aortal hypotension, caval hypertension

Ključne riječi
We introduce pentadecapeptide BPC 157 as the therapy of the hemodynamic disturbances in the prolonged suprahepatic occlusion of inferior caval vein (ICV) in rats mimicking Budd-Chiari syndrome. Previously, in rats with portal triad obstruction BPC 157 beneficially increased vessels branching in the intestinal serosa and counteracted intestinal lesions. It also counteracts free radical formation, and most importantly, counteracts portal hypertension and caval hypotension. In deeply anesthetized and laparatomized rats that have suprahepatic occlusion of ICV, the recording lasted 5 minutes with a cannula (assessed in one minute intervals) connected to a pressure transducer, inserted into the portal vein, inferior caval vein and abdominal aorta at the level of bifurcation, at 24 h or 48 h of ligation time. Medication (BPC 157), or saline (controls)) was applied in rats with suprahepatic occlusion of ICV, as an abdominal bath or as an intragastric application, at 24 h or 48 h reperfusion time. Assessment of portal, caval and aortal pressure showed huge portal hypertension and more caval hypertension along with mild aortic hypotension. Contrarily, when BPC 157 was given in those circumstances of the portal and caval hypertension, and arterial hypotension, these disturbances were marked counteracted. Thus, suprahepatic ICV occlusion provides high caval hypertension, even elevated in comparison to portal hypertension, and thereby, spontaneous decompression of the portal system can hardly be expected by a portocaval shunt. BPC 157, as an abdominal bath or as an intragastric application, may be a consistent therapy solution.

Hrčak ID: 224625

URI
https://hrcak.srce.hr/224625

Posjeta: 29 *